In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical Staphylococcal strains in Korea

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 mu g/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.